Simulated effects of microgravity, created by 60 days of constant bed rest, severely disrupts rhythmic gene expression in humans, according to a new study from the University of Surrey.
Harmony looks to buy rare disease drug developer in deal worth up to $200M
Harmony Biosciences is paying $60 million in cash to get its hands on Zynerba Pharmaceuticals and a therapy it’s developing to treat two rare diseases.
August 15, 2023